Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

In this video, Annick Desjardins, MD, professor of neurosurgery, professor of neurology and member of the Duke Cancer Institute, explains how clinicians may treat patients with gliomas of different ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings in cancer research ...

This metabolite disrupts normal cellular function and promotes tumor growth. Vorasidenib, a novel IDH inhibitor, works by deactivating the mutated IDH1/2 enzymes, halting the production of ...

Real-world survival differences in advanced biliary tract cancer patients with ctDNA detected IDH1 mutations and FGFR2 fusions receiving first-line gemcitabine-cisplatin with and without immunotherapy ...

Expanded biomarker analysis of an international, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune ...

Thanks to last year’s approval of IDH1/2 dual inhibitor Voranigo—which marked the first major treatment advance in low-grade brain cancer in more than two decades—Servier capped off 2024 ...

The FDA approved Vorasidenib, an IDH inhibitor. It works by blocking the mutated enzyme, slowing tumor growth, and extending the time before disease progression. IDH mutant gliomas tend to grow more ...